Propel Bio Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Propel Bio Management’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.25M	Buy	+85,791	New	+$1.37M	0.79%	34

Other funds holding CRVS

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Propel Bio Management's CRVS Position: Q1 2026 in Review

Propel Bio Management opened a new position in Corvus Pharmaceuticals (CRVS) in Q1 2026: 85,791 shares worth $1.25M. The stake represents 0.79% of the portfolio and ranks #34 among its holdings.

164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

Propel Bio Management held 85,791 shares of Corvus Pharmaceuticals worth $1.25M as of Q1 2026.
Corvus Pharmaceuticals was a new Propel Bio Management position in Q1 2026.
Corvus Pharmaceuticals made up 0.79% of Propel Bio Management's portfolio in Q1 2026, its #34 holding.
164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Propel Bio Management's 13F filing for Q1 2026, filed 14 May 2026.